135 related articles for article (PubMed ID: 2307844)
1. High-affinity binding of an influenza hemagglutinin-derived peptide to purified HLA-DR.
Roche PA; Cresswell P
J Immunol; 1990 Mar; 144(5):1849-56. PubMed ID: 2307844
[TBL] [Abstract][Full Text] [Related]
2. Effect of natural polymorphism at residue 86 of the HLA-DR beta chain on peptide binding.
Busch R; Hill CM; Hayball JD; Lamb JR; Rothbard JB
J Immunol; 1991 Aug; 147(4):1292-8. PubMed ID: 1869824
[TBL] [Abstract][Full Text] [Related]
3. Peptide binding to surface class II molecules is the major pathway of formation of immunogenic class II-peptide complexes for viable antigen presenting cells.
Nygard NR; Giacoletto KS; Bono C; Gorka J; Kompelli S; Schwartz BD
J Immunol; 1994 Feb; 152(3):1082-93. PubMed ID: 8301118
[TBL] [Abstract][Full Text] [Related]
4. Binding of labelled influenza matrix peptide to HLA DR in living B lymphoid cells.
Ceppellini R; Frumento G; Ferrara GB; Tosi R; Chersi A; Pernis B
Nature; 1989 Jun; 339(6223):392-4. PubMed ID: 2786148
[TBL] [Abstract][Full Text] [Related]
5. Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding.
Roche PA; Cresswell P
Nature; 1990 Jun; 345(6276):615-8. PubMed ID: 2190094
[TBL] [Abstract][Full Text] [Related]
6. Two processing pathways for the MHC class II-restricted presentation of exogenous influenza virus antigen.
Pinet V; Malnati MS; Long EO
J Immunol; 1994 May; 152(10):4852-60. PubMed ID: 8176208
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of polymorphism at HLA-DR1 beta-chain positions 85 and 86 on binding and recognition of DR1-restricted antigenic peptides.
Newton-Nash DK; Eckels DD
J Immunol; 1993 Mar; 150(5):1813-21. PubMed ID: 7679697
[TBL] [Abstract][Full Text] [Related]
8. Effect of pH on MHC class II-peptide interactions.
Sette A; Southwood S; O'Sullivan D; Gaeta FC; Sidney J; Grey HM
J Immunol; 1992 Feb; 148(3):844-51. PubMed ID: 1730877
[TBL] [Abstract][Full Text] [Related]
9. On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs.
O'Sullivan D; Arrhenius T; Sidney J; Del Guercio MF; Albertson M; Wall M; Oseroff C; Southwood S; Colón SM; Gaeta FC
J Immunol; 1991 Oct; 147(8):2663-9. PubMed ID: 1717570
[TBL] [Abstract][Full Text] [Related]
10. Presentation of cytosolic antigen by HLA-DR requires a function encoded in the class II region of the MHC.
Malnati MS; Ceman S; Weston M; DeMars R; Long EO
J Immunol; 1993 Dec; 151(12):6751-6. PubMed ID: 8258689
[TBL] [Abstract][Full Text] [Related]
11. Antigen presentation mediated by recycling of surface HLA-DR molecules.
Pinet V; Vergelli M; Martin R; Bakke O; Long EO
Nature; 1995 Jun; 375(6532):603-6. PubMed ID: 7540726
[TBL] [Abstract][Full Text] [Related]
12. Truncation analysis of several DR binding epitopes.
O'Sullivan D; Sidney J; Del Guercio MF; Colón SM; Sette A
J Immunol; 1991 Feb; 146(4):1240-6. PubMed ID: 1704034
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of binding capacities between HLA class II molecules and synthetic peptides HA307-319].
Ikeda K; Katagiri M
Hokkaido Igaku Zasshi; 1993 May; 68(3):318-24. PubMed ID: 8319931
[TBL] [Abstract][Full Text] [Related]
14. MHC class II function preserved by low-affinity peptide interactions preceding stable binding.
Sadegh-Nasseri S; Stern LJ; Wiley DC; Germain RN
Nature; 1994 Aug; 370(6491):647-50. PubMed ID: 8065450
[TBL] [Abstract][Full Text] [Related]
15. Invariant chain prevents the HLA-DR-restricted presentation of a cytosolic peptide.
Long EO; LaVaute T; Pinet V; Jaraquemada D
J Immunol; 1994 Aug; 153(4):1487-94. PubMed ID: 8046228
[TBL] [Abstract][Full Text] [Related]
16. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
Ramachandra L; Kovats S; Eastman S; Rudensky AY
J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
[TBL] [Abstract][Full Text] [Related]
17. Self-peptides from four HLA-DR alleles share hydrophobic anchor residues near the NH2-terminal including proline as a stop signal for trimming.
Kropshofer H; Max H; Halder T; Kalbus M; Muller CA; Kalbacher H
J Immunol; 1993 Nov; 151(9):4732-42. PubMed ID: 8409432
[TBL] [Abstract][Full Text] [Related]
18. Implication of HLA-DR residues at positions 67, 71, and 86 in interaction between HLA-DR11 and peptide HA306-320.
Zeliszewski D; Golvano JJ; Gaudebout P; Dorval I; Freidel C; Gebuhrer L; Betuel H; Borras-Cuesta F; Sterkers G
J Immunol; 1993 Dec; 151(11):6237-47. PubMed ID: 7504016
[TBL] [Abstract][Full Text] [Related]
19. Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen- or tumour-derived synthetic peptides.
Moro M; Cecconi V; Martinoli C; Dallegno E; Giabbai B; Degano M; Glaichenhaus N; Protti MP; Dellabona P; Casorati G
BMC Immunol; 2005 Dec; 6():24. PubMed ID: 16329759
[TBL] [Abstract][Full Text] [Related]
20. Properties of HLA class II molecules divergently associated with Goodpasture's disease.
Phelps RG; Jones V; Turner AN; Rees AJ
Int Immunol; 2000 Aug; 12(8):1135-43. PubMed ID: 10917888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
